Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 4, 2014, Pages 447-457

  Flouri, Irini ^a   Markatseli, Theodora E ^b   Voulgari, Paraskevi V ^b   Boki, Kyriaki A ^c   Papadopoulos, Ioannis ^d   Settas, Loukas ^e   Zisopoulos, Dimitrios ^e,f   Skopouli, Fotini N ^g   Iliopoulos, Alexios ^h   Bertsias, George K ^a   Geborek, Pierre ⁱ   Drosos, Alexandros A ^b   Boumpas, Dimitrios T ^a,j   Sidiropoulos, Prodromos ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d General Hospital of Kavala   (Greece)

^e ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^f 424 General Army Hospital   (Greece)

^g HAROKOPIO UNIVERSITY   (Greece)

^h Veterans Administration Hospital   (Greece)

ⁱ LUND UNIVERSITY   (Sweden)

^j UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

Arthritis; Biological therapies; Efficacy; Glucocorticoids; Infections; Registry; Safety

Indexed keywords

ARTHRITIS; BIOLOGICAL THERAPIES; EFFICACY; GLUCOCORTICOIDS; INFECTIONS; REGISTRY; SAFETY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84894903634     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.07.011     Document Type: Article

References (45)

1. Strand V., Kimberly R., Isaacs J.D. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007, 6(1):75-92.
2. Donahue K.E., Gartlehner G., Jonas D.E., Lux L.J., Thieda P., Jonas B.L., et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148(2):124-134.
3. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Can Med Assoc J 2009, 181(11):787-796.
4. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, (2)):CD008794.
5. Silverman S.L. From randomized controlled trials to observational studies. Am J Med 2009, 122(2):114-120.
6. Kievit W., Adang E.M., Fransen J., Kuper H.H., van de Laar M.A., Jansen T.L., et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008, 67(9):1229-1234.
7. Hetland M.L., Christensen I.J., Tarp U., Dreyer L., Hansen A., Hansen I.T., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62(1):22-32.
8. Canhao H., Rodrigues A.M., Mourao A.F., Martins F., Santos M.J., Canas-Silva J., et al. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(11):2020-2026.
9. Greenberg J.D., Reed G., Decktor D., Harrold L., Furst D., Gibofsky A., et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012, 71(7):1134-1142.
10. Lane M.A., McDonald J.R., Zeringue A.L., Caplan L., Curtis J.R., Ranganathan P., et al. TNF-alpha antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011, 90(2):139-145.
11. Grijalva C.G., Chen L., Delzell E., Baddley J.W., Beukelman T., Winthrop K.L., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. J Am Med Assoc 2011, 306(21):2331-2339.
12. van Dartel S.A., Fransen J., Kievit W., Flendrie M., den Broeder A.A., Visser H., et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis. 2012.
13. Markenson J.A., Gibofsky A., Palmer W.R., Keystone E.C., Schiff M.H., Feng J., et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 2011, 38(7):1273-1281.
14. Busquets N., Tomero E., Descalzo M.A., Ponce A., Ortiz-Santamaria V., Suris X., et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford) 2011, 50(11):1999-2004.
15. Atzeni F., Sarzi-Puttini P., Botsios C., Carletto A., Cipriani P., Favalli E.G., et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012, 12(2):225-229.
16. Iannone F., Gremese E., Atzeni F., Biasi D., Botsios C., Cipriani P., et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 2012, 39(6):1179-1184.
17. Drosos A.A., Moutsopoulos H.M. Rheumatoid arthritis in Greece: clinical, serological and genetic considerations. Clin Exp Rheumatol 1995, 13(Suppl. 12):S7-S12.
18. Sidiropoulos P., Flouri I. Update of the recommendations for the use of biological agents in rheumatoid arthritis and spondyloarthropathies [article in greek]. Hellenic Rheumatol 2008, 19(4):291-310.
19. Geborek P., Crnkic M., Petersson I.F., Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61(9):793-798.
20. Anderson J., Caplan L., Yazdany J., Robbins M.L., Neogi T., Michaud K., et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012, 64(5):640-647.
21. Woodworth T., Furst D., Strand V., Kempeni J., Fenner H., Lau C., et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001, 28(5):1163-1172.
22. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69(6):964-975.
23. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38(1):44-48.
24. Aletaha D., Smolen J.S. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007, 21(4):663-675.
25. Felson D.T., Smolen J.S., Wells G., Zhang B., van Tuyl L.H., Funovits J., et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 2011, 63(3):573-586.
26. van Gestel A.M., Prevoo M.L., van't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39(1):34-40.
27. Aletaha D., Martinez-Avila J., Kvien T.K., Smolen J.S. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012, 71(7):1190-1196.
28. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38(6):727-735.
29. Kristensen L.E., Saxne T., Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006, 54(2):600-606.
30. Mierau M., Schoels M., Gonda G., Fuchs J., Aletaha D., Smolen J.S. Assessing remission in clinical practice. Rheumatology (Oxford) 2007, 46(6):975-979.
31. Hyrich K.L., Watson K.D., Silman A.J., Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45(12):1558-1565.
32. Kristensen L.E., Kapetanovic M.C., Gulfe A., Soderlin M., Saxne T., Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008, 47(4):495-499.
33. Du Pan S.M., Dehler S., Ciurea A., Ziswiler H.R., Gabay C., Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009, 61(5):560-568.
34. Kristensen L.E., Saxne T., Nilsson J.A., Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006, 8(6):R174.
35. Gulfe A., Kristensen L.E., Geborek P. Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. J Rheumatol 2009, 36(3):517-521.
36. Molenaar E.T., Voskuyl A.E., Dinant H.J., Bezemer P.D., Boers M., Dijkmans B.A. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004, 50(1):36-42.
37. Lillegraven S., Prince F.H., Shadick N.A., Bykerk V.P., Lu B., Frits M.L., et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012, 71(5):681-686.
38. Jayakumar K., Norton S., Dixey J., James D., Gough A., Williams P., et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS. Rheumatology (Oxford) 2012, 51(1):169-175.
39. Sakai R., Tanaka M., Nanki T., Watanabe K., Yamazaki H., Koike R., et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis. 2012, 71(11):1820-1826.
40. Tang B., Rahman M., Waters H.C., Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008, 30(7):1375-1384.
41. Komano Y., Tanaka M., Nanki T., Koike R., Sakai R., Kameda H., et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J Rheumatol 2011, 38(7):1258-1264.
42. Sakai R., Komano Y., Tanaka M., Nanki T., Koike R., Nagasawa H., et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64(8):1125-1134.
43. Curtis J.R., Xie F., Chen L., Baddley J.W., Beukelman T., Saag K.G., et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011, 70(8):1401-1406.
44. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50(1):124-131.
45. Vandenbroucke J.P. Observational research, randomised trials, and two views of medical science. PLoS Med 2008, 5(3):e67.